Drugs Information:
Etretinate
Basic Information
|
||
ID | DDInter2024 | |
Drug Type | small molecule | |
Molecular Formula | C23H30O3 | |
Molecular Weight | 354.483 | |
CAS Number | 54350-48-0 | |
Description | Etretinate is a medication used to treat severe psoriasis. It is a synthetic aromatic retinoid. The mechanism of action of etretinate is still incompletely understood although, like retinoic acid, it is thought to interfere with the terminal differentiation of keratinocytes. It is thought to bind to the retinoic acid receptors. Etretinate is also believed to enhance the binding of cAMP to the regulatory RI subunit of cAMP dependent protein kinases. Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas. It also appears to inhibit NADH oxidase activity. | |
ATC Classification | D05BB01 | |
IUPAC Name | ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate | |
InChI | HQMNCQVAMBCHCO-DJRRULDNSA-N | |
Canonical SMILES | CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C | |
Useful Links | DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider BindingDB PharmGKB Wikipedia ChEMBL ZINC |
Interactions with
Etretinate
Filter:
Severity level | ID | Name | Mechanism | Detail |
---|
Interactions with diseases
Filter:
Severity level | Disease name | Text | References |
---|
Interactions with foods
Filter:
Severity level | Food name | Description | Management | Mechanism | References |
---|
Interactions with compound preparation
Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
---|